In its latest SEC filing for the third quarter, Banyan Capital Management Inc. established a new position in Johnson & Johnson by acquiring 3,853 shares valued at approximately $714,000. This addition represents 0.3% of Banyan’s total holdings, making JNJ its 22nd largest stake. The firm’s entry follows several other sizable institutional moves: Norges Bank initiated a $4.88 billion position in the second quarter, Laurel Wealth Advisors increased its JNJ share count by 7.37 million (a 15,040.6% rise) to 7.42 million shares worth $1.13 billion, and Vanguard Group added 3.09 million shares to reach 237.05 million shares valued at $36.21 billion. Geode Capital Management and Legal & General Group also boosted their exposure by 1.23 million and 1.10 million shares, respectively. Institutional investors now own 69.55% of JNJ’s outstanding shares.

European regulators delivered a positive opinion on AKEEGA (niraparib plus abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer, marking the first CHMP backing of a combination therapy in this indication and potentially expanding JNJ’s oncology revenue stream by hundreds of millions annually. In the U.S., a federal judge dismissed a fraud claim tied to JNJ’s talc bankruptcy strategy, removing near-term liability risk estimated at up to $500 million. However, legal analysts caution that broader talc litigation continues in state courts, leaving a contingent exposure that could range into low-single-digit billions over time.

Following JNJ’s solid fourth-quarter results—revenue growth of 9.1% year-over-year to $24.56 billion and EPS matching consensus at $2.46—sell-side analysts have grown more bullish. Daiwa Capital Markets raised its rating to Outperform with a $237 target, Morgan Stanley upgraded the stock citing a stronger growth outlook, and Scotiabank reiterated Outperform while lifting its target to $265. Consensus among 26 analysts tracks a Moderate Buy with an average target of $233.05. Separately, JNJ’s dividend was set at $1.30 per share for the quarter (annualized $5.20, payout ratio 47.1%), reinforcing a 60-year streak of increases and supporting its 2.3% current yield.